IL6 and prostate carcinoma: In prostate cancer, pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8), or transforming growth factor-beta (TGF-β) have been implicated in disease progression and resistance to therapy [6].